Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series

2018 ◽  
Vol 32 (7) ◽  
pp. e13303
Author(s):  
Isabel Campos-Varela ◽  
Eliana Z. Agudelo ◽  
Norah A. Terrault
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Antiviral Treatment ◽  
Case Series ◽  
Direct Acting Antivirals ◽  
Transplant Patients ◽  
Direct Acting

Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals

2014 ◽  
Vol 35 ◽  
pp. 44-50 ◽  
Author(s):  
Audrey Coilly ◽  
Bruno Roche ◽  
Jean-Charles Duclos-Vallée ◽  
Didier Samuel
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Direct Acting Antivirals ◽  
Optimal Therapy ◽  
Transplant Patients ◽  
Direct Acting

scholarly journals Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review

2021 ◽  
Vol 8 (11) ◽  
Author(s):  
Kristen Whelchel ◽  
Autumn D Zuckerman ◽  
David E Koren ◽  
Caroline Derrick ◽  
Jeannette Bouchard ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Literature Review ◽  
Case Series ◽  
Direct Acting Antivirals ◽  
Limited Data ◽  
Hcv Treatment ◽  
Direct Acting

Abstract Limited data exist regarding the use of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in patients who are unable to swallow tablets. This case series describes HCV treatment in patients requiring tablet manipulation, providing evidence for safety and effectiveness of HCV DAA tablet manipulation.

Hepatitis C Virus Infection in Maintenance Hemodialysis Patients: Recommendations for Diagnostics and Treatment

2016 ◽  
Vol 39 (12) ◽  
pp. 590-595 ◽  
Author(s):  
Pavlina Dzekova-Vidimliski ◽  
Aleksandar Sikole
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Antiviral Agents ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Direct Acting Antivirals ◽  
Hcv Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Hepatitis C virus (HCV) infection is highly prevalent among patients treated with maintenance hemodialysis and is an important cause of morbidity and mortality. It is necessary to determine the HCV genotype and the viral load to monitor the clinical and laboratory features and to establish an optimal antiviral treatment strategy. Antiviral treatments are presented with a standard interferon-based regimen and new direct-acting antiviral agents. The advent of direct-acting antivirals has improved the efficacy and safety of HCV treatment for most patients, even in difficult-to-treat populations such as patients on hemodialysis. HCV treatment with direct-acting antivirals in hemodialysis patients is highly effective, with viral eradication rates similar to those seen in patients without chronic kidney disease and with acceptable adverse event profiles.

scholarly journals Impact of direct‐acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients

2019 ◽  
Vol 21 (3) ◽  
pp. e13078 ◽  
Author(s):  
Alexandra L. Bixby ◽  
Linda Fitzgerald ◽  
Rachael Leek ◽  
Jessica Mellinger ◽  
Pratima Sharma ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Liver Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document